0001415889-24-004108.txt : 20240216 0001415889-24-004108.hdr.sgml : 20240216 20240216161108 ACCESSION NUMBER: 0001415889-24-004108 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240215 FILED AS OF DATE: 20240216 DATE AS OF CHANGE: 20240216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gravier Pierre CENTRAL INDEX KEY: 0001984065 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35969 FILM NUMBER: 24648443 MAIL ADDRESS: STREET 1: C/O PTC THERAPEUTICS, INC. STREET 2: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001070081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 043416587 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 BUSINESS PHONE: 9082227000 MAIL ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 FORMER COMPANY: FORMER CONFORMED NAME: PTC THERAPEUTICS INC DATE OF NAME CHANGE: 19980909 4 1 form4-02162024_040248.xml X0508 4 2024-02-15 0001070081 PTC THERAPEUTICS, INC. PTCT 0001984065 Gravier Pierre C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 false true false false CHIEF FINANCIAL OFFICER 0 Common Stock 2024-02-15 4 A 0 19000 0 A 52700 D Common Stock 2024-02-15 4 A 0 3100 0 A 55800 D Stock Option (Right to Buy) 25.69 2024-02-15 4 A 0 47500 0 A 2034-02-14 Common Stock 47500 47500 D Restricted stock units granted on February 15, 2024 that vest in four equal installments over four years, commencing on February 15, 2025. Restricted stock units granted on February 15, 2024 that vest in two equal installments over two years, commencing on February 15, 2025. This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. /s/ Avraham S. Adler, Attorney-in-Fact 2024-02-16